indazoles has been researched along with docetaxel anhydrous in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Belvin, M; Eastham-Anderson, J; Friedman, LS; Gunter, B; Haverty, PM; Hoeflich, KP; Lee-Hoeflich, ST; Lewin-Koh, N; Murray, LJ; Sliwkowski, MX; Truong, T; Yao, E; Zhou, W | 1 |
| Guo, F; Khamly, K; Michael, M; Olszanski, AJ; Pierce, KJ; Vlahovic, G | 1 |
| Flaig, TW; Li, Y; Su, LJ; Yang, X | 1 |
| Bair, AH; Bycott, P; Chan, S; Joy, AA; Kim, S; Liau, KF; Lluch, A; Rosbrook, B; Rugo, HS; Soulieres, D; Stopeck, AT; Verma, S | 1 |
| Schneider, BP; Sledge, GW | 1 |
| Belmont, LD; Belvin, M; Berry, L; Friedman, LS; Guan, J; Koeppen, H; Lee, LB; Prior, WW; Sampath, D; Wallin, JJ | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| de Bruijn, P; de Jonge, MJ; Eskens, FA; Hamberg, P; Leonowens, C; Mathijssen, RH; Sleijfer, S; van der Biessen, D; Verweij, J | 1 |
| Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA | 1 |
| Fujita, H; Kadono, T; Kimura, T; Masui, Y; Miyagaki, T; Miyagawa, T; Saigusa, R; Sato, S; Yamada, D; Yoshizaki, A | 1 |
| Fader, AN; Ricci, S; Stone, RL | 1 |
| Ahn, JB; Choi, YD; Chung, HC; Han, JW; Heo, SJ; Hur, H; Kim, HS; Kim, JH; Kim, KS; Kim, S; Kim, SH; Kim, SK; Lee, YH; Noh, SH; Park, HS; Rha, SY; Shin, KH; Suh, JS | 1 |
| Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z | 1 |
| Anand, M; Armstrong, AJ; Barak, I; George, DJ; Halabi, S; Harrison, MR; Healy, P; Klein, M; Martinez, E; Nixon, AB; Szmulewitz, R; Wilder, R; Winters, C | 1 |
| Li, J; Liang, X; Shen, Q; Sun, L; Yang, J; Zhang, J; Zuo, T | 1 |
| Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
1 review(s) available for indazoles and docetaxel anhydrous
| Article | Year |
|---|---|
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Chemotherapy, Adjuvant; Deoxycytidine; Diagnostic Errors; Dioxoles; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Hysterectomy; Indazoles; Laparoscopy; Leiomyoma; Leiomyosarcoma; Morcellation; Neoplasm Staging; Pyrimidines; Sulfonamides; Taxoids; Tetrahydroisoquinolines; Trabectedin; Uterine Myomectomy; Uterine Neoplasms | 2017 |
6 trial(s) available for indazoles and docetaxel anhydrous
| Article | Year |
|---|---|
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bilirubin; Creatinine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Patient Selection; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2010 |
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypertension; Imidazoles; Indazoles; Middle Aged; Mucositis; Neoplasm Proteins; Neutropenia; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Taxoids; Thrombophilia | 2011 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Taxoids | 2015 |
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
9 other study(ies) available for indazoles and docetaxel anhydrous
| Article | Year |
|---|---|
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Humans; Indazoles; Lapatinib; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
Topics: Antineoplastic Agents; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Indazoles; Pyrimidines; Sulfonamides; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2011 |
Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Guidelines as Topic; Humans; Imidazoles; Indazoles; Multicenter Studies as Topic; Neoplasm Proteins; Precision Medicine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research Design; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Survival; Docetaxel; Drug Synergism; Female; Humans; Indazoles; Mice; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides; Taxoids | 2012 |
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemothera
Topics: Abdomen; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dermatofibrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Ifosfamide; Indazoles; Male; Mesna; Middle Aged; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2019 |
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Coadministration of chemotherapy and PI3K/Akt pathway treatment with multistage acidity/CathB enzyme-responsive nanocarriers for inhibiting the metastasis of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Indazoles; Maleic Anhydrides; Mice; Nanoparticles; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Polyethyleneimine; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |